Taken together, the animal studies showed good safety, efficacy, and preclinical PK characteristics of QX002N injection, indicating that QX002N injection is a viable candidate for clinical application as an anti-IL-17A monoclonal antibody to treat psoriasis and AS. Here, IL17A is linked to psoriasis.